ENTX — Entera Bio Ltd.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1638097 ·
Israel
Last close
$3.00
Market Cap
$521.77M
52W High
$4.20
52W Low
$0.91
ADV30
451,546
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | -7,265,000 | -15,597,000 | 277,040,000 | 265,883,000 | 2,758,000 |
| Jun 2026 | 0 | 0 | -4,563,000 | -7,312,000 | 19,480,000 | 11,309,000 | 12,214,000 |
| Mar 2026 | 0 | 0 | -3,539,000 | -3,505,000 | 13,129,000 | 4,137,000 | 2,442,000 |
| Dec 2025 | 0 | 0 | -3,042,000 | -3,016,000 | 15,993,000 | 7,108,000 | 2,892,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,889,000
Investing CF
$-73,000
Financing CF
$10,513,000
CapEx
$-107,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.34
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-136,183,000
Inventory
—
Receivables
$105,000
ST Investments
—
EBIT TTM
$-14,400,000
Pretax Income TTM
$-17,033,000
Interest Exp TTM
$2,749,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-14,369,000
Free Cash Flow
$-6,684,875
Enterprise Value
$532,781,344
Total Cash
$11,309,000
Total Debt
$425,000
Shares Out
173,922,428
Trailing EPS
$-0.36
Book Value
$0.28
ROE
-138.9%
ROA
-46.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 42,000 | -11,529,000 | -11,439,000 | 15,993,000 | 2,892,000 | 13,101,000 | -7,370,000 |
| Dec 2024 | 181,000 | -9,585,000 | -9,541,000 | 9,390,000 | 1,310,000 | 8,080,000 | -6,818,000 |
| Dec 2023 | 0 | -8,891,000 | -8,889,000 | 11,765,000 | 1,379,000 | 10,386,000 | -7,310,000 |
| Dec 2022 | 134,000 | -13,017,000 | -13,071,000 | 13,127,000 | 1,373,000 | 11,754,000 | -12,499,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$17,033,000
OpCashFlow TTM
—
Assets (Latest)
$19,480,000
Forward EPS
$-0.55
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $3.26 · call volume: 156 · put volume: 10Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ETRA | Electra Therapeutics, Inc. | $524.10M | $8.35 | — |
| VALN | Valneva SE | $527.69M | $5.57 | — |
| SANA | Sana Biotechnology, Inc. | $563.31M | $1.88 | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $479.44M | $13.58 | — |
| RGNX | REGENXBIO Inc. | $478.73M | $7.24 | — |
News headlines (Yahoo Finance, 1h cache)
Entera Announces Third Quarter 2026 Financial Results and Business Updates
2026-11-06 21:15 · Yahoo
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
2026-10-27 12:00 · Yahoo
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at AS
2026-10-13 11:00 · Yahoo
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
2026-10-08 12:00 · Yahoo
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
2026-10-06 12:00 · Yahoo
Entera to Participate in Upcoming Fall Investor Conferences
2026-08-27 12:00 · Yahoo
Entera Bio shares slip as Q2 loss comes in wider than expected
2026-08-10 11:02 · Yahoo
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-07-31 20:30 · Yahoo
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
2026-07-27 12:30 · Yahoo
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
2026-06-22 18:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.